GLP-1 mediated diuresis and natriuresis are blunted in heart failure and restored by selective afferent renal denervation.
Animals
Capsaicin
/ administration & dosage
Disease Models, Animal
Diuresis
/ drug effects
Diuretics
/ administration & dosage
Glucagon-Like Peptide 1
/ administration & dosage
Heart Failure
/ drug therapy
Infusions, Intravenous
Kidney
/ drug effects
Male
Natriuresis
/ drug effects
Rats, Sprague-Dawley
Sympathectomy, Chemical
Glucagon-like peptide-1
Heart failure
Renal afferent
Sodium and water homeostasis
Sympathetic nerve activity
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
08 05 2020
08 05 2020
Historique:
received:
11
02
2020
accepted:
25
04
2020
entrez:
10
5
2020
pubmed:
10
5
2020
medline:
27
10
2020
Statut:
epublish
Résumé
Glucagon-like peptide-1 (GLP-1) induces diuresis and natriuresis. Previously we have shown that GLP-1 activates afferent renal nerve to increase efferent renal sympathetic nerve activity that negates the diuresis and natriuresis as a negative feedback mechanism in normal rats. However, renal effects of GLP-1 in heart failure (HF) has not been elucidated. The present study was designed to assess GLP-1-induced diuresis and natriuresis in rats with HF and its interactions with renal nerve activity. HF was induced in rats by coronary artery ligation. The direct recording of afferent renal nerve activity (ARNA) with intrapelvic injection of GLP-1 and total renal sympathetic nerve activity (RSNA) with intravenous infusion of GLP-1 were performed. GLP-1 receptor expression in renal pelvis, densely innervated by afferent renal nerve, was assessed by real-time PCR and western blot analysis. In separate group of rats after coronary artery ligation selective afferent renal denervation (A-RDN) was performed by periaxonal application of capsaicin, then intravenous infusion of GLP-1-induced diuresis and natriuresis were evaluated. In HF, compared to sham-operated control; (1) response of increase in ARNA to intrapelvic injection of GLP-1 was enhanced (3.7 ± 0.4 vs. 2.0 ± 0.4 µV s), (2) GLP-1 receptor expression was increased in renal pelvis, (3) response of increase in RSNA to intravenous infusion of GLP-1 was enhanced (132 ± 30% vs. 70 ± 16% of the baseline level), and (4) diuretic and natriuretic responses to intravenous infusion of GLP-1 were blunted (urine flow 53.4 ± 4.3 vs. 78.6 ± 4.4 µl/min/gkw, sodium excretion 7.4 ± 0.8 vs. 10.9 ± 1.0 µEq/min/gkw). A-RDN induced significant increases in diuretic and natriuretic responses to GLP-1 in HF (urine flow 96.0 ± 1.9 vs. 53.4 ± 4.3 µl/min/gkw, sodium excretion 13.6 ± 1.4 vs. 7.4 ± 0.8 µEq/min/gkw). The excessive activation of neural circuitry involving afferent and efferent renal nerves suppresses diuretic and natriuretic responses to GLP-1 in HF. These pathophysiological responses to GLP-1 might be involved in the interaction between incretin-based medicines and established HF condition. RDN restores diuretic and natriuretic effects of GLP-1 and thus has potential beneficial therapeutic implication for diabetic HF patients.
Sections du résumé
BACKGROUND
Glucagon-like peptide-1 (GLP-1) induces diuresis and natriuresis. Previously we have shown that GLP-1 activates afferent renal nerve to increase efferent renal sympathetic nerve activity that negates the diuresis and natriuresis as a negative feedback mechanism in normal rats. However, renal effects of GLP-1 in heart failure (HF) has not been elucidated. The present study was designed to assess GLP-1-induced diuresis and natriuresis in rats with HF and its interactions with renal nerve activity.
METHODS
HF was induced in rats by coronary artery ligation. The direct recording of afferent renal nerve activity (ARNA) with intrapelvic injection of GLP-1 and total renal sympathetic nerve activity (RSNA) with intravenous infusion of GLP-1 were performed. GLP-1 receptor expression in renal pelvis, densely innervated by afferent renal nerve, was assessed by real-time PCR and western blot analysis. In separate group of rats after coronary artery ligation selective afferent renal denervation (A-RDN) was performed by periaxonal application of capsaicin, then intravenous infusion of GLP-1-induced diuresis and natriuresis were evaluated.
RESULTS
In HF, compared to sham-operated control; (1) response of increase in ARNA to intrapelvic injection of GLP-1 was enhanced (3.7 ± 0.4 vs. 2.0 ± 0.4 µV s), (2) GLP-1 receptor expression was increased in renal pelvis, (3) response of increase in RSNA to intravenous infusion of GLP-1 was enhanced (132 ± 30% vs. 70 ± 16% of the baseline level), and (4) diuretic and natriuretic responses to intravenous infusion of GLP-1 were blunted (urine flow 53.4 ± 4.3 vs. 78.6 ± 4.4 µl/min/gkw, sodium excretion 7.4 ± 0.8 vs. 10.9 ± 1.0 µEq/min/gkw). A-RDN induced significant increases in diuretic and natriuretic responses to GLP-1 in HF (urine flow 96.0 ± 1.9 vs. 53.4 ± 4.3 µl/min/gkw, sodium excretion 13.6 ± 1.4 vs. 7.4 ± 0.8 µEq/min/gkw).
CONCLUSIONS
The excessive activation of neural circuitry involving afferent and efferent renal nerves suppresses diuretic and natriuretic responses to GLP-1 in HF. These pathophysiological responses to GLP-1 might be involved in the interaction between incretin-based medicines and established HF condition. RDN restores diuretic and natriuretic effects of GLP-1 and thus has potential beneficial therapeutic implication for diabetic HF patients.
Identifiants
pubmed: 32384887
doi: 10.1186/s12933-020-01029-0
pii: 10.1186/s12933-020-01029-0
pmc: PMC7206815
doi:
Substances chimiques
Diuretics
0
Glucagon-Like Peptide 1
89750-14-1
Capsaicin
S07O44R1ZM
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
57Subventions
Organisme : NHLBI NIH HHS
ID : P01 HL062222
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK114663
Pays : United States
Références
J Card Fail. 2017 Sep;23(9):702-707
pubmed: 28645757
Am J Physiol Renal Physiol. 2011 Mar;300(3):F641-9
pubmed: 21159737
Auton Neurosci. 2017 May;204:35-47
pubmed: 27717709
Peptides. 2018 Jan;99:27-35
pubmed: 29113826
BMC Neurosci. 2012 Mar 23;13:33
pubmed: 22443187
Am J Physiol Renal Physiol. 2012 Oct;303(7):F963-71
pubmed: 22832924
J Diabetes Investig. 2016 Apr;7 Suppl 1:64-9
pubmed: 27186358
Nat Rev Cardiol. 2018 May;15(5):282-291
pubmed: 29368701
Endocrinology. 2018 Apr 1;159(4):1570-1584
pubmed: 29444223
Biosci Rep. 2019 Dec 20;39(12):
pubmed: 31763669
Eur J Pharmacol. 2017 Sep 15;811:38-47
pubmed: 28576404
J Cardiol. 2018 May;71(5):471-476
pubmed: 29415819
Am J Physiol Regul Integr Comp Physiol. 2002 Apr;282(4):R1006-15
pubmed: 11893604
Lancet. 2015 May 23;385(9982):2067-76
pubmed: 25765696
J Pharmacol Toxicol Methods. 2007 Jul-Aug;56(1):1-10
pubmed: 17391988
Am J Physiol. 1984 Oct;247(4 Pt 2):R615-20
pubmed: 6496710
Circ Res. 2014 May 23;114(11):1788-803
pubmed: 24855202
Circ Heart Fail. 2016 Nov;9(11):
pubmed: 27810863
Eur J Pharmacol. 2020 Mar 15;871:172936
pubmed: 31958459
Circ Heart Fail. 2009 Mar;2(2):138-44
pubmed: 19808329
J Mol Neurosci. 2002 Feb-Apr;18(1-2):7-14
pubmed: 11931352
Circ Res. 2012 Jun 22;111(1):131-50
pubmed: 22595296
Hypertension. 2018 Sep;72(3):667-675
pubmed: 30012866
Am J Physiol Renal Physiol. 2015 Apr 15;308(8):F867-77
pubmed: 25656368
Front Pharmacol. 2018 Sep 27;9:1092
pubmed: 30319423
Cardiovasc Pathol. 2020 Jan - Feb;44:107160
pubmed: 31759320
Nat Rev Nephrol. 2017 Oct;13(10):605-628
pubmed: 28869249
N Engl J Med. 2016 Nov 10;375(19):1834-1844
pubmed: 27633186
Am J Physiol Regul Integr Comp Physiol. 2012 Aug 15;303(4):R387-94
pubmed: 22718804
Compr Physiol. 2017 Mar 16;7(2):263-320
pubmed: 28333375
Cardiovasc Diabetol. 2011 Sep 28;10:85
pubmed: 21955567
Am J Physiol Heart Circ Physiol. 2015 May 1;308(9):H1103-11
pubmed: 25637549
Am J Physiol Renal Physiol. 2006 Dec;291(6):F1148-56
pubmed: 16822936
Hypertens Res. 2018 Oct;41(10):798-808
pubmed: 29985448
Am J Physiol Regul Integr Comp Physiol. 2013 Oct 15;305(8):R886-92
pubmed: 24005248
Circulation. 2014 Oct 28;130(18):1579-88
pubmed: 25189213
Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1738-46
pubmed: 12969886
JAMA. 2016 Aug 2;316(5):500-8
pubmed: 27483064
Diabetes Metab. 2017 Apr;43 Suppl 1:2S13-2S19
pubmed: 28431666
J Clin Endocrinol Metab. 2019 Jul 1;104(7):2509-2519
pubmed: 30835273
Cell Metab. 2016 Jul 12;24(1):15-30
pubmed: 27345422
Auton Neurosci. 2002 Nov 29;102(1-2):39-44
pubmed: 12492134
Eur J Heart Fail. 2018 Apr;20(4):627-629
pubmed: 29082598
Cardiovasc Diabetol. 2018 Jun 12;17(1):85
pubmed: 29895290
Am J Physiol. 1996 Oct;271(4 Pt 2):H1441-8
pubmed: 8897938
Eur J Pharmacol. 2013 Jan 5;698(1-3):74-86
pubmed: 23051671
Front Pharmacol. 2019 Oct 23;10:1267
pubmed: 31708787
Am J Physiol Heart Circ Physiol. 2019 Nov 1;317(5):H958-H968
pubmed: 31490733
Am J Hypertens. 2014 Feb;27(2):260-7
pubmed: 24096926
Cardiovasc Diabetol. 2019 Oct 22;18(1):138
pubmed: 31640705
Int J Cardiol. 2013 Jan 20;162(3):189-92
pubmed: 23031283
Nitric Oxide. 2019 Jun 1;87:73-82
pubmed: 30878404
Biochem Biophys Res Commun. 2014 Aug 22;451(2):276-81
pubmed: 25089000
J Clin Invest. 2014 Oct;124(10):4473-88
pubmed: 25202980
Physiol Rev. 2007 Oct;87(4):1409-39
pubmed: 17928588
Circulation. 2018 Dec 18;138(25):2908-2918
pubmed: 30566006
Am J Physiol. 1993 Oct;265(4 Pt 2):R923-8
pubmed: 8238466
Circ Heart Fail. 2017 Oct;10(10):
pubmed: 29021350
Circulation. 2004 Aug 24;110(8):955-61
pubmed: 15313949
Cardiovasc Diabetol. 2018 Jan 11;17(1):12
pubmed: 29325553
Endocrinology. 2013 Jan;154(1):4-8
pubmed: 23267050
Nat Med. 2013 May;19(5):567-75
pubmed: 23542788
Am J Physiol Heart Circ Physiol. 2016 Aug 1;311(2):H337-46
pubmed: 27288440
Neuropeptides. 2017 Oct;65:77-82
pubmed: 28624122
Curr Cardiol Rep. 2012 Jun;14(3):285-92
pubmed: 22392370
N Engl J Med. 2016 Jul 28;375(4):311-22
pubmed: 27295427
Am J Physiol Regul Integr Comp Physiol. 2015 Jan 15;308(2):R112-22
pubmed: 25411365
J Cardiovasc Transl Res. 2020 Feb 4;:
pubmed: 32020504
Physiol Rep. 2017 Dec;5(23):
pubmed: 29233907
Hypertension. 2016 Dec;68(6):1415-1423
pubmed: 27698066
Compr Physiol. 2011 Apr;1(2):731-67
pubmed: 23737201
Am J Physiol Regul Integr Comp Physiol. 2006 Apr;290(4):R1035-43
pubmed: 16322353
Endocrinology. 2014 Apr;155(4):1280-90
pubmed: 24467746
J Clin Invest. 2002 Jul;110(1):43-52
pubmed: 12093887
Am J Physiol Renal Physiol. 2019 Oct 1;317(4):F1010-F1021
pubmed: 31390233
Circ Heart Fail. 2010 Jul;3(4):512-21
pubmed: 20466848